Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Carcinoma, Basal Cell 8Medulloblastoma 6Recurrence 4Skin Neoplasms 3Basal Cell Nevus Syndrome 3Thrombocythemia, Essential 2Prostatic Neoplasms 2Primary Myelofibrosis 2Polycythemia Vera 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Glioma 2Glioblastoma 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Astrocytoma 2Thrombocytosis 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Pyloric Stenosis, Hypertrophic 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pinealoma 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Diseases 1

Interventions

Cyclophosphamide 20Brentuximab Vedotin 20fludarabine 16Lenalidomide 13Rituximab 12Dexamethasone 12fludarabine phosphate 10Melphalan 10Busulfan 10Mycophenolic Acid 9dacetuzumab 7Whole-Body Irradiation 7Tacrolimus 7pirtobrutinib 6Doxorubicin 6Bortezomib 6Azacitidine 6ruxolitinib 5Vincristine 5Prednisone 5Imatinib Mesylate 5ponatinib 4pomalidomide 4Mesna 4Granulocyte Colony-Stimulating Factor 4Etoposide 4Bone Marrow Transplantation 4Bendamustine Hydrochloride 4venetoclax 3nilotinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hematologic Diseases × sonidegib × Clear all
NCT01787552 2020-04-15

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Novartis

Phase 1/2 Completed
50 enrolled 23 charts
Myeloid

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡